It is clear that identifying poor compounds early through scientific rigor is key in preventing progression into more expensive preclinical tests. Even a minor improvement in early-stage drug failure prediction will result in significant time and cost savings for R&D companies.
Specifically, XenoGesis can identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis. We combine our state-of-the-art in vitro, in vivo and bioanalytical capabilities with our expert pharmacokinetic/pharmacodynamic (PK/PD) data interpretation services.
Using this integrated approach we provide you with the information required to successfully achieve your drug discovery goals.